anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a microbial ecological agent for quickly and efficiently preventing and treating pig high fever, which is prepared from beneficial microorganisms, Chinese herbal medicine extracts, animal appetite promoter and the like. The invention provides the microbial ecological agent for preventing and treating the pig high fever. The technical scheme comprises the following steps of: culturing tea fungus solution or preparing tea fungus powder; and preparing liquoric root, chrysanthemum and honeysuckle flower extracting solution. In the treating formula, the microbial ecological agent comprises the following components: 10 to 30 percent of tea fungus powder or tea fungus solution, 10 to 30 percent of Chinese medicinal extracting solution, 5 to 10 percent of sugar, 0.5 to 2 percent of sodium chloride, 0.5 to 2 percent of mature vinegar, 0.1 to 5 percent of ammonium sulfate, 0.1 to 5 percent of monopotassium phosphate and the balance of plain boiled water or sterile water. The microbial ecological agent can be directly fed or statically cultured at the temperature of between 25 and 35 DEG C for 12 to 24 hours, and then is used for preventing and treating the pig high fever. The microbial ecological agent has the advantages of quick response and high efficiency. Generally, the appetite of a sick pig can be obviously improved and the sick pig can be better next day when fed with the microbial ecological agent for 1 day (twice per day); the microbial ecological agent makes the anorectic sick pig with the pig high fever take food; the sick pig can be basically recovered after being continuously fed for 3 to 7 days; and the cure rate can reach over 90 percent.
BACKGROUND: Fanconi-Bickel syndrome (FBS) is a rare autosomal recessive disorder characterized by impaired glucose and galactose utilization as well as proximal renal tubular dysfunction.
METHODS: Clinical, biochemical, genetic, treatment, and follow-up data for 11 pediatric patients with FBS were retrospectively analysed.
RESULTS: Hepatomegaly (10/11), short stature (10/11) and hypophosphataemic rickets (7/11) were the most common initial symptoms. At diagnosis, all patients had decreased fasting blood glucose (FBG), plasma bicarbonate (HCO3-) and serum phosphorus, as well as elevated liver transaminases, alkaline phosphatase (AKP) and proximal renal tubular dysfunction. Two infant patients were misdiagnosed with transient neonatal diabetes mellitus. After therapy with uncooked cornstarch and conventional rickets treatment, remission of hepatomegaly was observed in all patients, with significant improvements in pre-prandial blood glucose, liver transaminases, triglyceride, plasma HCO3- and AKP (p < 0.05). At the last follow-up, 5/7 patients with elevated AKP had nephrocalcinosis. The mean height standard deviation score (Ht SDS) of eight patients with regular treatment increased from - 4.1 to -3.5 (p = 0.02). Recombinant human growth hormone (rhGH) was administered to 4/9 patients, but their Ht SDS did not improve significantly (p = 0.13). Fourteen variants of the SLC2A2 gene were identified, with six being novel, among which one was recurrent: c.1217T > G (p.L406R) (allele frequency: 4/22, 18%). Patients with biallelic missense variants showed milder metabolic acidosis than those with null variants. Two of five patients from nonconsanguineous families with rare homozygous variations showed 5.3 Mb and 36.6 Mb of homozygosity surrounding the variants, respectively; a region of homozygosity (ROH) involving the entire chromosome 3 covering the SLC2A2 gene, suggesting uniparental disomy 3, was detected in one patient.
CONCLUSIONS: Early diagnosis of FBS is difficult due to the heterogeneity of initial symptoms. Although short stature is a major issue of treatment for FBS, rhGH is not recommended in FBS patients who have normal GH stimulation tests. Patients with biallelic null variants may require alkali supplementation since urine bicarbonate loss is genetically related. ROH is a mechanism for rare homozygous variants of FBS in nonconsanguineous families.
Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10\^7, 0.1×10\^7, 1.0×10\^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
PURPOSE:To obtain a food additive, prepared from a natural product and capable of stably and sufficiently inhibiting the activity function of an angiotensin- converting enzyme(ACE). CONSTITUTION:This food additive comprises an extract obtained by freeze-drying at least one selected from the group consisting of a flower of Brassica campestris L. subsp. napus Hook. fil. et Anders. var. nippo-oleifera Makino, a leaf of Italian parsley, a leaf of Petroselinum cripsum Nym., a leaf of Aralia cordata Thunb., a leaf of Humulus lupulus L. var. cordifolius Maxim., a flower of Chaenomeles japonica Lindl. ex Spach, a leaf and a flower of Pueraria thunbergiana Benth., a flower and a fruit of Angelica polyclada Franch., a leaf of Allium ascalonicum (shallot), a leaf of Rumex Acetosa L., a leaf of Anethum graveolens L. (dill), the whole herb of Lactura dentata Makino, the whole herb of Anemone flaccida Fr. Schm., a flower of Erigeron annuus L., a leaf of Mentha piperita L., a leaf of Brassica juncea Czern. et Coss, a leaf of Sanguisorba officinalis L., a flower and a leaf of Centaurea cyanus L. and a flower of Wistaria brachybotrys Sieb. et Zucc., then pulverizing the freeze- dried substance and subsequently extracting the pulverized substance with water.
NEW MATERIAL:To fluorescent mono-, di- or polyamide of an aminomonocarboxylic acid and a tetrapyrrole containing >=3 carboxyl groups and represented by the formula (Z is aminomonocarboxylic acid residue free from amino group; X is tetrapyrrole residue free from carboxyl group; n is integer of 1-4). EXAMPLE:Di-L-serinylrhodine g7. USE:Agent for photodiagnosis and phototherapy of tumor and cancer tissue. Since the compound is easily secreted from the host, the photosensitization of the host can be decreased. PREPARATION:An amino acid and a tetrapyrrole containing >=3 carboxyl groups (e.g. chlorin e6) are used as starting raw materials. The materials are made to contact with each other in a solvent such as DMF preferably in the presence of a carbodiimide such as N/N'dicyclohexylcarbodiimide, etc., to effect the condensation of the starting compounds.
Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
PURPOSE: A composition for preventing or curing the metabolic syndrome related-diseases is provided to prevent or cure metabolic syndrome-related diseases including the obesity the hyperlipidemia, the hypertension, the arteriosclerosis, or the hyperinsulinemia etc. by using a 4-hydroxytamoxifen analog (GSK5182) which suppresses a fat synthesis, lowering glucose levels in blood, reducing the total cholesterol in blood, and reducing body fat. CONSTITUTION: A pharmaceutical composition for preventing or curing metabolic syndrome related-diseases comprises the chemical formula 1 of 4-hydroxy tamoxifen analog or its pharmaceutically acceptable salt as an active ingredient. The composition additionally comprises a pharmaceutically acceptable carrier. The metabolic syndrome related-diseases are more than one selected from a group comprising the obesity, the hyperlipidemia, the hypertension, the arteriosclerosis, and the hyperinsulinemia. The composition suppresses accumulation of fat, and reduces size of fat cell and body fat. [Reference numerals] (AA) Weight; (BB) Fat weight; (CC) Before injection; (DD) After injection; (EE,GG,KK,JJ) Control group; (FF,HH,LL) GSK5182 injected group; (II) Fat ratio
CSBP/p38 is a MAP kinase that is activated in response to stress, endotoxin, interleukin 1 and tumor necrosis factor. Using a catalytically inactive mutant (D168A) of human CSBP2 as the bait in a yeast two-hybrid screen, a kinase has been cloned which shares ˜70% amino acid identity to MAPKAP kinase-2, and thus was designated MAPKAP kinase-3. The binding of CSBP to MAPKAP kinase 3 was confirmed in vitro by the precipitation of epitope-tagged CSBP1, CSBP2 and CSBP2(D168A) and endogenous CSBP from mammalian cells by a bacterially-expressed GST-MAPKAP kinase-3 fusion protein and in vivo by co-precipitation of the epitope-tagged proteins co-expressed in HeLa cells. MAPKAP kinase-3 was phosphorylated by both CSBP1 and CSBP2, and was then able to phosphorylate HSP27 in vitro. Treatment of HeLa cells with sorbitol or TNF resulted in activation of CSBP and MAPKAP kinase-3 and activation of MAPKAP kinase-3 could be blocked by preincubation of cells with 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-4-pyridyl)-1H-imidazole, a specific inhibitor of CSBP kinase activity. These data suggest that MAPKAP kinase-3 is activated by stress and cytokines and is a novel substrate of CSBP both in vitro and in vivo. The use of MAPKAP kinase-3 in screens for the identification of pharmaceutically active compounds is disclosed.
The invention especially relates to an aqueous, perspiration-absorbent cosmetic product, e.g. a deodorant, containing a perspiration-absorbent complex. The invention further relates to a method for producing said complex and said cosmetic product. The inventive cosmetic product contains: i) a basic formulation; and ii) a perspiration-absorbent complex comprising (a) at least one water-absorbent component, (b) at least one surfactant, (c) at least one electrolyte, and (d) at least one solvent and/or at least one carrier substance, the perspiration-absorbent complex in the basic formulation being provided in the form of emulsified particles. Said particles are composed of a three-dimensional, water-swellable network of the at least one water-absorbent component while being surrounded at least in part by the at least one surfactant. The at least one electrolyte is incorporated at least in part in intermediate spaces of the three-dimensional network of the at least one water-absorbent component.
A study of 24 completed subjects will be conducted by enrolling patients who are requiring treatment for open skin and soft tissue defects. Patients will be screened for inclusion criteria and asked to consent to participate in the study. Following consent subjects will be randomized to receive treatment of one of the two study arms. Arm 1, the standard of care arm, will receive KCI Wound VAC Granulofoam. Arm 2, the study arm, will receive treatment with NP-PWD. Prior to the initial application, wound evaluations and photography will be completed to include assessment of infection with wound swabs. The wound dressing will be assessed for the need for change every 2-3 days and changed if clinically indicated (following each device IFU). Subjects will be followed for up to nine days post initial application. At minimum, the randomized treatment will be applied for 2 days after initial application for a subject to be considered completed. Subject who do not complete the treatment course (minimum of 2 days of treatment), may be replaced per investigators discretion. Follow up data will be gathered at each change/removal of the NP-PWD or Wound VAC. The data collected will include indications for dressing change, dressing change process, photographs and assessments for wound healing, infection, and adverse events. Gathered clinical data of the enrolled subjects will be used to evaluate the feasibility in using the NP-PWD device for wound healing management.
This application relates to lipid nanoparticles, which include: a helper lipid and an ionizable lipid, at least one lipid layer surrounding an interior having at least one aqeous portion, an encapsulated inorganic particle, and an agent of interest (e.g. therapeutic, diagnostic, or theranostic agents). The ionizable lipid is present at between 2 mol% and 30 mol% relative to total lipid. The agent of interest is a hydrophilic agent present in the at least one aqueous portion or is a lipophilic agent present in the at least one lipid layer. This application also relates to methods of making the lipid nanoparticle, as well as methods of using the lipid nanoparticle (e.g. for therapy or diagnostics), including using external stimuli (e.g. laser irradiation) to release the agent of interest.
To investigate the potential clinical value of urinary exosomal (uE) miR-451a as a biomarker for IgAN, urinary exosomes were isolated from 40 patients with IgAN, 30 patients with primary renal diseases without IgA as disease controls (non-IgAN group) and 21 healthy controls (HCs). The expression of miR-451a within exosomes was examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). uE miR-451a was significantly upregulated in patients with IgAN compared to non-IgAN and HCs. The uE miR-451a level was positively correlated with the change in eGFR and negatively correlated with serum creatinine, urinary macrophage migration inhibitory factor (MIF), interleukin-6 (IL-6) and tumor necrosis factor (TNF-α). A dual-luciferase reporter assay confirmed that MIF was a direct target of miR-451a. Receiver operating characteristic (ROC) curve analysis revealed that the expression of uE miR-451a showed potential diagnostic value for IgAN. Additionally, the uE miR-451a level could distinguish patients with IgAN with mild tubular atrophy/interstitial fibrosis from those with severe tubular atrophy/interstitial fibrosis. After a mean follow-up of 14.2 months, the levels of eGFR loss (ml/min/1.73 m2/year) were negatively correlated with baseline miR-451a. The levels of baseline miR-451a in the complete remission group were significantly higher than those in the non-complete remission group. uE miR-451a expression was significantly elevated in patients with IgA nephropathy and may serve as a potential biomarker for the diagnosis of IgAN and evaluation of tubulointerstitial damage, while the baseline levels of uE miR-451a may be predictors of therapeutic efficacy and disease progression.
Intervention involves the consumption of White Bread (standard food): 86g of crustless white sandwich bread as the standard food to reach the 50g of available CHO. Subjects administer rapid-acting insulin before consumption based on their ratio and sensitivity.
Breast cancer is the most common type of invasive cancer in women, with more than 1 million cases and almost 600,000 deaths occurring worldwide annually. Breast cancer that has spread to other parts of the body (metastasized) is usually not curable. Patients with a type of metastatic breast cancer that has hormone receptors on the surface of the cancer cells are usually treated with the drug tamoxifen, which interferes with the function of these hormone receptors. However, the average survival time for these patients remains at around 36 months.

In patients who no longer respond to tamoxifen (hormone-refractory breast cancer), the cancer drug trastuzumab (Herceptin), which acts on a protein called human epidermal growth factor receptor 2 (HER2), may have some activity. In addition, studies suggest that the drug everolimus, which acts on a pathway within cancer cells that is important for growth of the tumor, may make the cancer cells more sensitive to treatment with trastuzumab. Thus, the two drugs may act together to increase their anti-cancer potential.
1. A herbicidal composition comprising molinate and oxyfluorfen in a weight ratio of from about 500:1 to about 30:1. 2. A herbicidal composition according to claim I in which the weight ratio is from about 250:3.25 to about 5:1. 3. A herbicidal composition according to claim I in which the weight ratio is from about 250:1 to about 40:1. 4. A herbicidal composition according to claim 1 which is liquid. 5. A herbicidal composition according to claim 1 which is solid. 6. A herbicidal composition according to claim 1 characterized by a controlled release of active substances. 7. A herbicidal composition according to claim 6 in which at least one of molinate and oxyfluorfen is contained in microcapsules. 8. A method of controlling weeds in the presence of a rice crop comprising applying to said crop, said weeds, or the locus of said crop and/or said weeds, a herbicidally-effective amount of a composition according to any of claims 1 to 7.
Functional constipation is a common clinical diagnosis that affects approximately 14% of the world's population. Non-pharmacological therapies often represent the initial steps in management and may include lifestyle adjustments or changes such as physical activity and diet. Pharmacological options have been used when the non-pharmacological approach has been ineffective. Biofeedback therapy, surgery, sacral nerve stimulation, botulinum toxin injection, and vibrating capsules can be considered in scenarios where the laxatives are ineffective. Biofeedback therapy is highly effective and safe in treating dyssynergic defecation, which affects more than half of patients with chronic constipation. This paper overviews non-pharmacological therapies for functional constipation.
Chronic pain is a pathological state defined as daily pain sensation over three consecutive months. It affects up to 30% of the general population. Although significant research efforts have been made in the past 30 years, only a few and relatively low effective molecules have emerged to treat chronic pain, with a considerable translational failure rate. Most preclinical models have focused on sensory neurotransmission, with particular emphasis on the dorsal horn of the spinal cord as the first relay of nociceptive information. Beyond impaired nociceptive transmission, chronic pain is also accompanied by numerous comorbidities, such as anxiety-depressive disorders, anhedonia and motor and cognitive deficits gathered under the term "pain matrix". The emergence of cutting-edge techniques assessing specific neuronal circuits allow in-depth studies of the connections between "pain matrix" circuits and behavioural outputs. Pain behaviours are assessed not only by reflex-induced responses but also by various or more complex behaviours in order to obtain the most complete picture of an animal's pain state. This review summarises the latest findings on pain modulation by brain component of the pain matrix and proposes new opportunities to unravel the mechanisms of chronic pain.
PURPOSE: A polysaccharide extracted from Capsosiphon fulvescens with anti-thrombotic effect and immunity is provided to produce a large amount of polysaccharide without side effects. CONSTITUTION: A polysaccharide having anti-thrombotic effect and immunity is isolated from Capsosiphon fulvescens. The polysaccharide is a soluble polysaccharide containing sulfate residue. The polysaccharide contains mannose and galactose as a main ingredient. A composition contains the polysaccharide as an active ingredient. A method for preparing the polysaccharide comprises: a step of neutralizing hydrolyzed extract of Capsosiphon fulvescens; a step of precipitating with alcohol of 1-4 carbon atoms, ethyl acetate, hexane, dichloromethane, or mixture solvent thereof and centrifuging to obtain a first precipitate; a step of treating the first precipitate with calcium chloride(CaCl_2) and centrifuging to obtain a supernatant; a step of treating the supernatant with alcohol of 1-4 carbon atoms, ethyl acetate, hexane, dichloromethane, or mixture solvent thereof to obtain a second precipitate; and a step of dialyzing the second precipitate and drying.
12.1 Mechanism of Action

The primary action of ChiRhoStim ® is to stimulate pancreatic ductal cells to secrete pancreas fluid in large volumes that contain bicarbonate. 

Secretin is a hormone that is normally released from the duodenum upon exposure of the proximal intestinal lumen to gastric acid, fatty acids and amino acids. Secretin is released from enterochromaffin cells in the intestinal mucosa. Secretin receptors have been identified in the pancreas, stomach, liver, colon and other tissues. When secretin binds to secretin receptors on pancreatic duct cells it opens cystic fibrosis transmembrane conductance regulator (CFTR) channels, leading to secretion of bicarbonate-rich-pancreatic fluid. Secretin may also work through vagal-vagal neural pathways since stimulation of the efferent vagus nerve stimulates bicarbonate secretion and atropine blocks secretin-stimulated pancreatic secretion.
OBJECTIVE: Depression is one of the common manifestations of diabetes population, and previous studies have shown that there is a correlation between depression and diabetes. This study was conducted retrospectively through the large National Health and Nutrition Examination Survey (NHANES) to explore the risk of depression in different individuals with diabetes.
METHODS: We collected data on a total of 33,001 individuals in 5 cycles of NHANES and compared the incidence of depression in the individuals with diabetes, pre-diabetes or without diabetes groups after weighting. A weighted logistic review was used to assess the association between diabetes and depression at different BMI, sex, and age levels. Mediating analysis was used to assess the risk of depression in people with obesity-mediated diabetes. In addition, the non-linear relationship between BMI and depression at different factor levels was evaluated using restricted cubic strips (RCS).
RESULTS: Diabetes was significantly associated with depression in obesity, especially for female (OR: 1.45, 95 % CI: 1.20-1.75, P < 0.001) and young (<Age 60 years old) (OR: 2.03, 95 % CI: 1.31-3.15, P = 0.002). Mediating analysis showed that obesity explained 28.6 % of the risk of depression in people with diabetes. The RCS curve further confirms the non-linear relationship between BMI and depression risk, that is, regardless of age, sex, and diabetes, the risk of depression increases with BMI. At the same BMI level, diabetes, youth (age < 60) and women have a higher risk of depression.
CONCLUSIONS: There is a significant correlation between diabetes and depression, and obesity as a mediating variable mediates the correlation between diabetes and depression. Especially in obese, young (age < 60) and women, the phenomenon is more pronounced.
Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.